MGNX - MacroGenics: Strong Likelihood Bad News Has Caused Overreaction (Rating Upgrade)
2024-05-13 05:51:23 ET
Summary
- Macrogenics' stock valuation has dropped over 70% after its first quarter update, creating a new opportunity for investors.
- The spotlight is on their product vobramitamab duocarmazine, and the phase 2 TAMARACK trial.
- Macrogenics has between 4 and 5 quarters of cash and investments on hand.